Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Achieve Life Sciences Initiates Pivotal Trial Of Cytisinicline For Smoking Cessation

Achieve Life Sciences Inc (NASDAQ:ACHV) has initiated the screening in the ORCA-3 Phase 3 trial of cytisinicline for smoking cessation.

  • The trial will evaluate the efficacy and safety of 3 mg cytisinicline dosed three times daily compared to placebo in 750 adult smokers.
  • ORCA-3 participants will be randomized to one of three study arms to evaluate cytisinicline administered for either 6 or 12 weeks, compared to placebo.
  • Related: Achieve Life Sciences Secures $25M Loan Facility To Fund Smoking Cessation Program.
  • The primary outcome measure of success in the ORCA-3 trial is biochemically verified continuous abstinence during the last four weeks of treatment in the 6 and 12-week cytisinicline treatment arms compared with placebo. 
  • Each treatment arm will be compared independently to the placebo arm. 
  • Secondary outcome measures will be conducted to assess continued abstinence rates through 6 months from the start of study treatment.
  • Achieve recently announced completed the last subject visit in the ongoing Phase 3 ORCA-2 trial, with topline data results expected in Q2 of 2022. 
  • Additionally, the Phase 2 ORCA-V1 study, which is expected to investigate the efficacy of cytisinicline in approximately 150 adult nicotine e-cigarette users, is anticipated to initiate by the end of Q2 of 2022.
  • Price Action: ACHV shares are up 0.85% at $7.14 during the market session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.